Private M&A 2024: Key Trends and Forecasts
What Goes On Inside Your Boardroom? Investors Want To Know
Public M&A Day in Frankfurt
Global Dealmaking in 2013: Why the Best Strategies will Dominate
In Dealmaker’s Digest, read the top 10 latest developments in global transactions. We offer insights into M&A activity across industries and borders. Global deal value in March dwarfed activity in January and February, driven...more
During this session, the panelists discussed notable developments within the life sciences industry with a specific focus on the GLP-1 drug market and its opportunities for improvement in patient satisfaction and dosage. They...more
After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention - Overall, pharma, medical...more
Dealmaking in the pharma, medical and biotech (PMB) subsectors was driven by both old and new market trends in 2022 - Following a ground-breaking year for dealmaking in 2021, global healthcare M&A remained robust in 2022,...more
In line with overall M&A trends, global private equity had a blockbuster 2021 by any metric, but perhaps the best is this: In a record-setting year for global M&A, a record was also set for the percentage of M&A deals that...more
The value of healthcare M&A in H1 surpassed pre-pandemic levels - Healthcare M&A (including pharma, biotech and medical) saw strong growth over the first half of 2021 as investors continued to pursue deal opportunities in...more
Technology M&A activity is thriving in 2021 as dealmakers continue to turn to the sector in search of assets with high-quality earnings and growth prospects - Technology deal volume and value surged through the first half...more